Characteristics of recurrence after completing adjuvant tamoxifen therapy for 5 years

被引：0
|
作者：
Lee, Eunshin [1 ]
Lee, Han-Byoel [1 ]
Kang, Young Joon [1 ]
Kim, Yun-Gyoung [1 ]
Yoo, Tae-kyung [1 ]
Kim, Jongjin [1 ]
Kim, Min Kyoon [1 ]
Moon, Hyeong-Gon [1 ]
Noh, Dong-Young [1 ]
Han, Wonshik [1 ]
机构：
[1] Seoul Natl Univ, Coll Med, Seoul 151, South Korea
来源：
CANCER RESEARCH | 2015年 / 75卷
关键词：
D O I：
10.1158/1538-7445.SABCS14-P1-12-07
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P1-12-07
引用
收藏
页数：2
相关论文
共 50 条
  • [41] TAMOXIFEN RECHALLENGE - RESPONSE TO TAMOXIFEN FOLLOWING RELAPSE AFTER ADJUVANT CHEMOHORMONAL THERAPY FOR BREAST-CANCER
    MUSS, HB
    SMITH, LR
    COOPER, MR
    JOURNAL OF CLINICAL ONCOLOGY, 1987, 5 (10) : 1556 - 1558
  • [42] Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer
    Howell, A
    Cuzick, J
    Baum, M
    Buzdar, A
    Dowsett, M
    Forbes, JF
    Hoctin-Boes, G
    Houghton, I
    Locker, GY
    Tobias, JS
    LANCET, 2005, 365 (9453): : 60 - 62
  • [43] Efficacy data from the ATAC ("arimidex", tamoxifen, alone or in combination) trial after completion of 5 years' adjuvant treatment
    不详
    BREAST, 2005, 14 : S51 - S51
  • [44] A COMPARISON OF 2 AND 3 YEARS OF ADJUVANT TAMOXIFEN
    WOLMARK, N
    REDMOND, C
    FISHER, B
    HORMONE RESEARCH, 1989, 32 : 166 - 168
  • [45] Recurrence of invasive cervical carcinoma more than 5 years after initial therapy
    Takehara, K
    Shigemasa, K
    Sawasaki, T
    Naito, H
    Fujii, T
    OBSTETRICS AND GYNECOLOGY, 2001, 98 (04): : 680 - 684
  • [46] Salvage of recurrence after surgery and adjuvant therapy: A systematic review
    Zenga, Joseph
    Gross, Jennifer
    Fowler, Susan
    Chen, Jenny
    Vila, Peter
    Richmon, Jeremy D.
    Varvares, Mark A.
    Pipkorn, Patrik
    AMERICAN JOURNAL OF OTOLARYNGOLOGY, 2018, 39 (02) : 223 - 227
  • [47] Isolated recurrence of prostate cancer to the anterior urethra 5 years after radiation therapy
    Fujiwara, Shinnosuke
    Ishida, Masaru
    Arai, Eri
    Baba, Yuto
    Anno, Tadatsugu
    Kobayashi, Hiroaki
    Miyazaki, Yasumasa
    IJU CASE REPORTS, 2022, 5 (01) : 58 - 61
  • [48] Benefit from exemestane (EXE) as extended adjuvant therapy after 5 years of tamoxifen (TAM): intent-to-treat analysis of NSABP B-33.
    Mamounas, E.
    Jeong, J-H
    Wickerham, L.
    Smith, R.
    Geyer, C.
    Ganz, P.
    Land, S.
    Hutchins, L.
    Eisen, A.
    Ingle, J.
    Costantino, J.
    Wolmark, N.
    BREAST CANCER RESEARCH AND TREATMENT, 2006, 100 : S22 - S22
  • [49] Cognitive function in postmenopausal breast cancer patients one year after completing adjuvant endocrine therapy with letrozole and/or tamoxifen in the BIG 1-98 trial
    Kelly-Anne Phillips
    Julie Aldridge
    Karin Ribi
    Zhuoxin Sun
    Alastair Thompson
    Vernon Harvey
    Beat Thürlimann
    Fatima Cardoso
    Olivia Pagani
    Alan S. Coates
    Aron Goldhirsch
    Karen N. Price
    Richard D. Gelber
    Jürg Bernhard
    Breast Cancer Research and Treatment, 2011, 126 : 221 - 226
  • [50] Cognitive function in postmenopausal breast cancer patients one year after completing adjuvant endocrine therapy with letrozole and/or tamoxifen in the BIG 1-98 trial
    Phillips, Kelly-Anne
    Aldridge, Julie
    Ribi, Karin
    Sun, Zhuoxin
    Thompson, Alastair
    Harvey, Vernon
    Thuerlimann, Beat
    Cardoso, Fatima
    Pagani, Olivia
    Coates, Alan S.
    Goldhirsch, Aron
    Price, Karen N.
    Gelber, Richard D.
    Bernhard, Juerg
    BREAST CANCER RESEARCH AND TREATMENT, 2011, 126 (01) : 221 - 226
12345